Company intelligence / Profile preview
NeurogesX
San Mateo, California, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
NeurogesX developed Qutenza, a capsaicin-based treatment for neuropathic pain, which was approved in the U.S. and EU. The company also had NGX-1998 in clinical trials but is no longer active.
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- Small moleculestopical formulations
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Astellas Pharma Europe Ltd. for Qutenza marketing in Europe
Beyond the preview
Go deeper on NeurogesX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeurogesX.